All In Biotech

Drug Trial Radar · NCT00630110

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Aug 16, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 172 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

172

Actual

Start

Feb 2008

Primary completion

Jun 2011

Study completion Jun 2011

Sponsor

Lead sponsor
Nereus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 6, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues.

Conditions

  • Cancer

Interventions

  • docetaxelDrug

    docetaxel (75 mg/m2)

  • NPI-2358 + docetaxelDrug

    NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare overall survival of patients treated with docetaxel to patients treated with docetaxel + NPI-2358Time frame: Continuous

Locations

36 sites in 6 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Scottsdale, Arizona

  • San Diego Pacific Oncology & Hematology Associates

    Encinitas, California

  • University San Diego Moores Cancer Center

    San Diego, California

  • Kaiser Permanente

    San Diego, California

  • Premiere Oncology

    Santa Monica, California

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • University Texas Health Science Center at San Antonio (CTRC)

    San Antonio, Texas

  • Policlinica Privada Instituto de Medicina Nuclear

    Bahía Blanca, Argentina

  • Hospital Britanico

    Capital Federal, Argentina

  • Instituto Oncologico De Cordoba

    Córdoba, Argentina

  • Clinica Universitaria Privada Reina Fabiola

    Córdoba, Argentina

  • Caici Centro de Asistencia e Investigacion Clinica Integral

    Rosario, Argentina

  • Hospital del Centrenario

    Rosario, Argentina

  • Mater Adult Hospital

    South Brisbane, Queensland, Australia

  • Bendigo Health Care Group

    Bendigo, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • Fundacap Pip XII Hospital do Cancer de Barretos

    Barretos, Brazil

  • Hospital Erasto Gaertner Liga do Combate as Cancer

    Curitiba, Brazil

  • Associacao Hospital de Caridade Ijui

    Ijuí, Brazil

  • Hospital Sao Lucas

    Porte Alegre, Brazil

  • Hospital de clinicas de Porto Alegre

    Porto Alegre, Brazil

  • Clinionco-Clinica de Oncologia de Porto Alegre

    Porto Alegre, Brazil

  • Hosp.das Clinicas da Univ.de Sao Paulo

    São Paulo, Brazil

  • Instituto do Cancer Aenaldo Vieira de Carvahlo

    São Paulo, Brazil

  • Instituto Nacional del Cancer Oncology

    Santiago, Chile

  • Hospital Carlos Van Buren

    Valparaíso, Chile

  • Kidwai Memorial Institute of Oncology

    Bangalore, India

  • Apollo Speciality Hospital

    Chennai, India

  • Apollo Hospital

    Hyderabad, India

  • SEAROC Cancer Centre S.K. Soni Hospital

    Jaipur, India

  • Subodh Mitra Cancer Hospital & Research Centre

    Kolkata, India

  • Tata Memorial Hospital

    Mumbai, India

  • Ruby Hall Clinic

    Pune, India

  • Andhra Medical College

    Visakhapatnam, India

  • Chittaranjan National Cancer Institute

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.